ENDRA Life Sciences (NASDAQ:NDRA) Price Target Lowered to $50.00 at Ascendiant Capital Markets

ENDRA Life Sciences (NASDAQ:NDRA) had its price target dropped by equities research analysts at Ascendiant Capital Markets from $75.00 to $50.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

ENDRA Life Sciences Stock Performance

Shares of NASDAQ:NDRA opened at $3.67 on Monday. The firm’s 50 day simple moving average is $4.15 and its 200-day simple moving average is $5.55. ENDRA Life Sciences has a one year low of $3.02 and a one year high of $664.83. The firm has a market cap of $2.06 million, a PE ratio of 0.00 and a beta of 0.19.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Monday, March 31st. The company reported ($9.40) EPS for the quarter, missing the consensus estimate of ($4.10) by ($5.30). Equities research analysts predict that ENDRA Life Sciences will post -47.46 EPS for the current fiscal year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.